Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices 30063 

1 50 U.S.C. 4558(c)(1). 

2 85 FR 18403 (Apr. 1, 2020). 

3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020); 

DHS Delegation Number 09052 Rev. 00 (Jan. 3, 

2017). 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: June 14, 2021. 

Open: 11:00 a.m. to 12:00 p.m. 

Agenda: NCAB Subcommittee Meetings— 

Subcommittee on Planning and Budget. 

Open: 12:05 p.m. to 4:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Director’s report and 

presentations. 

Closed: 4:00 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: June 15, 2021. 

Open: 1:00 p.m. to 3:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Board of Scientific 

Advisors Concepts Review, Ongoing and 

New Business. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D. 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

NCAB: https://deainfo.nci.nih.gov/ 

advisory/ncab/ncabmeetings.htm, 

BSA: https://deainfo.nci.nih.gov/advisory/ 

bsa/bsameetings.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

difficulties. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: June 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11783 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Cancer Institute. 

The meeting will be closed to the public 

as indicated below in accordance with 

the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Cancer Institute. 

Date: July 12–13, 2021. 

Time: 11:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Brian E. Wojcik, Ph.D., 

Senior Review Administrator, Institute 

Review Office, Office of the Director, 

National Cancer Institute, National Institutes 

of Health, 9609 Medical Center Drive, Room 

3W414, Rockville, MD 20850, 240–276–5660, 

wojcikb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: June 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11784 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0016] 

Meetings To Implement Pandemic 

Response Voluntary Agreement Under 

Section 708 of the Defense Production 

Act 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Announcement of meetings. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) held two 

meetings to implement the Voluntary 

Agreement for the Manufacture and 

Distribution of Critical Healthcare 

Resources Necessary to Respond to a 

Pandemic. 

DATES: The first meeting took place on 

Tuesday, May 25, 2021, from 10:30 a.m. 

to 12 p.m. Eastern Time (ET). The 

second meeting took place on 

Wednesday, May 26, 2021, from 2 to 3 

p.m. ET. 

FOR FURTHER INFORMATION CONTACT: 

Robert Glenn, Office of Business, 

Industry, Infrastructure Integration, via 

email at OB3I@fema.dhs.gov or via 

phone at (202) 212–1666. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is provided as required 

by section 708(h)(8) of the Defense 

Production Act (DPA), 50 U.S.C. 

4558(h)(8), and consistent with 44 CFR 

part 332. 

The DPA authorizes the making of 

‘‘voluntary agreements and plans of 

action’’ with representatives of industry, 

business, and other interests to help 

provide for the national defense.1 The 

President’s authority to facilitate 

voluntary agreements with respect to 

responding to the spread of COVID–19 

within the United States was delegated 

to the Secretary of Homeland Security 

in Executive Order 13911.2 The 

Secretary of Homeland Security further 

delegated this authority to the FEMA 

Administrator.3

On August 17, 2020, after the 

appropriate consultations with the 

Attorney General and the Chairman of 

the Federal Trade Commission, FEMA 

completed and published in the Federal 

Register a ‘‘Voluntary Agreement, 

Manufacture and Distribution of Critical 

Healthcare Resources Necessary to